- Home
- CYBN vs IPHA Comparison
CYBN vs IPHA Comparison
Compare CYBN & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBN
- IPHA
- Stock Information
- Founded
- CYBN 2019
- IPHA 1999
- Country
- CYBN Canada
- IPHA France
- Employees
- CYBN N/A
- IPHA N/A
- Industry
- CYBN Pharmaceuticals and Biotechnology
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- CYBN Health Care
- IPHA Health Care
- Exchange
- CYBN Nasdaq
- IPHA Nasdaq
- Market Cap
- CYBN 178.7M
- IPHA 160.1M
- IPO Year
- CYBN N/A
- IPHA 2019
- Fundamental
- Price
- CYBN $7.54
- IPHA $2.15
- Analyst Decision
- CYBN Strong Buy
- IPHA Strong Buy
- Analyst Count
- CYBN 4
- IPHA 1
- Target Price
- CYBN $85.00
- IPHA $11.00
- AVG Volume (30 Days)
- CYBN 412.3K
- IPHA 13.3K
- Earning Date
- CYBN 08-12-2025
- IPHA 09-11-2025
- Dividend Yield
- CYBN N/A
- IPHA N/A
- EPS Growth
- CYBN N/A
- IPHA N/A
- EPS
- CYBN N/A
- IPHA N/A
- Revenue
- CYBN N/A
- IPHA $20,831,349.00
- Revenue This Year
- CYBN N/A
- IPHA $278.51
- Revenue Next Year
- CYBN N/A
- IPHA $70.16
- P/E Ratio
- CYBN N/A
- IPHA N/A
- Revenue Growth
- CYBN N/A
- IPHA N/A
- 52 Week Low
- CYBN $4.81
- IPHA $1.29
- 52 Week High
- CYBN $13.88
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- CYBN 46.24
- IPHA 63.83
- Support Level
- CYBN $7.26
- IPHA $1.71
- Resistance Level
- CYBN $7.81
- IPHA $2.63
- Average True Range (ATR)
- CYBN 0.45
- IPHA 0.14
- MACD
- CYBN -0.04
- IPHA 0.04
- Stochastic Oscillator
- CYBN 17.72
- IPHA 47.83
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.